321 related articles for article (PubMed ID: 37117135)
61. Targeting the tumor microenvironment to overcome immune checkpoint blockade therapy resistance.
Li Y; Liu J; Gao L; Liu Y; Meng F; Li X; Qin FX
Immunol Lett; 2020 Apr; 220():88-96. PubMed ID: 30885690
[TBL] [Abstract][Full Text] [Related]
62. Exploring novel immune-related toxicities and endpoints with immune-checkpoint inhibitors in non-small cell lung cancer.
Chow LQ
Am Soc Clin Oncol Educ Book; 2013; ():. PubMed ID: 23714523
[TBL] [Abstract][Full Text] [Related]
63. Cancer immunotherapy-related adverse events: causes and challenges.
Blidner AG; Choi J; Cooksley T; Dougan M; Glezerman I; Ginex P; Girotra M; Gupta D; Johnson D; Shannon VR; Suarez-Almazor M; Rapoport BL; Anderson R
Support Care Cancer; 2020 Dec; 28(12):6111-6117. PubMed ID: 32857220
[TBL] [Abstract][Full Text] [Related]
64. Safety and Tolerability of Immune Checkpoint Inhibitors (PD-1 and PD-L1) in Cancer.
Baraibar I; Melero I; Ponz-Sarvise M; Castanon E
Drug Saf; 2019 Feb; 42(2):281-294. PubMed ID: 30649742
[TBL] [Abstract][Full Text] [Related]
65. Immune checkpoints and cancer development: Therapeutic implications and future directions.
Mehdizadeh S; Bayatipoor H; Pashangzadeh S; Jafarpour R; Shojaei Z; Motallebnezhad M
Pathol Res Pract; 2021 Jul; 223():153485. PubMed ID: 34022684
[TBL] [Abstract][Full Text] [Related]
66. Resident Kupffer cells and neutrophils drive liver toxicity in cancer immunotherapy.
Siwicki M; Gort-Freitas NA; Messemaker M; Bill R; Gungabeesoon J; Engblom C; Zilionis R; Garris C; Gerhard GM; Kohl A; Lin Y; Zou AE; Cianciaruso C; Bolli E; Pfirschke C; Lin YJ; Piot C; Mindur JE; Talele N; Kohler RH; Iwamoto Y; Mino-Kenudson M; Pai SI; deVito C; Koessler T; Merkler D; Coukos A; Wicky A; Fraga M; Sempoux C; Jain RK; Dietrich PY; Michielin O; Weissleder R; Klein AM; Pittet MJ
Sci Immunol; 2021 Jul; 6(61):. PubMed ID: 34215680
[TBL] [Abstract][Full Text] [Related]
67. Immune checkpoint therapy-current perspectives and future directions.
Sharma P; Goswami S; Raychaudhuri D; Siddiqui BA; Singh P; Nagarajan A; Liu J; Subudhi SK; Poon C; Gant KL; Herbrich SM; Anandhan S; Islam S; Amit M; Anandappa G; Allison JP
Cell; 2023 Apr; 186(8):1652-1669. PubMed ID: 37059068
[TBL] [Abstract][Full Text] [Related]
68. Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance.
Martins F; Sofiya L; Sykiotis GP; Lamine F; Maillard M; Fraga M; Shabafrouz K; Ribi C; Cairoli A; Guex-Crosier Y; Kuntzer T; Michielin O; Peters S; Coukos G; Spertini F; Thompson JA; Obeid M
Nat Rev Clin Oncol; 2019 Sep; 16(9):563-580. PubMed ID: 31092901
[TBL] [Abstract][Full Text] [Related]
69. Mechanisms of Immune-Related Complications in Cancer Patients Treated with Immune Checkpoint Inhibitors.
König D; Läubli H
Pharmacology; 2021; 106(3-4):123-136. PubMed ID: 32721966
[TBL] [Abstract][Full Text] [Related]
70. [Physiopathological mechanisms of immune-related adverse events induced by anti-CTLA-4, anti-PD-1 and anti-PD-L1 antibodies in cancer treatment].
Passat T; Touchefeu Y; Gervois N; Jarry A; Bossard C; Bennouna J
Bull Cancer; 2018 Nov; 105(11):1033-1041. PubMed ID: 30244981
[TBL] [Abstract][Full Text] [Related]
71. PD-1/PD-L1 Blockade Therapy in Advanced Non-Small-Cell Lung Cancer: Current Status and Future Directions.
Xia L; Liu Y; Wang Y
Oncologist; 2019 Feb; 24(Suppl 1):S31-S41. PubMed ID: 30819829
[TBL] [Abstract][Full Text] [Related]
72. Next steps in immuno-oncology: enhancing antitumor effects through appropriate patient selection and rationally designed combination strategies.
Salama AK; Moschos SJ
Ann Oncol; 2017 Jan; 28(1):57-74. PubMed ID: 28177433
[TBL] [Abstract][Full Text] [Related]
73. Immunotherapy of thymic epithelial tumors: molecular understandings and clinical perspectives.
Ao YQ; Gao J; Wang S; Jiang JH; Deng J; Wang HK; Xu B; Ding JY
Mol Cancer; 2023 Apr; 22(1):70. PubMed ID: 37055838
[TBL] [Abstract][Full Text] [Related]
74. Immune Checkpoint Inhibitors and Cardiac Toxicity: An Emerging Issue.
Varricchi G; Marone G; Mercurio V; Galdiero MR; Bonaduce D; Tocchetti CG
Curr Med Chem; 2018; 25(11):1327-1339. PubMed ID: 28403786
[TBL] [Abstract][Full Text] [Related]
75. The Current Landscape of Immune Checkpoint Blockade in Metastatic Lung Squamous Cell Carcinoma.
Yuan H; Liu J; Zhang J
Molecules; 2021 Mar; 26(5):. PubMed ID: 33807509
[TBL] [Abstract][Full Text] [Related]
76. Immune-related adverse events of checkpoint inhibitors: Insights into immunological dysregulation.
Yang H; Yao Z; Zhou X; Zhang W; Zhang X; Zhang F
Clin Immunol; 2020 Apr; 213():108377. PubMed ID: 32135278
[TBL] [Abstract][Full Text] [Related]
77. Enhancing cancer immunotherapy: Exploring strategies to target the PD-1/PD-L1 axis and analyzing the associated patent, regulatory, and clinical trial landscape.
Kirthiga Devi SS; Singh S; Joga R; Patil SY; Meghana Devi V; Chetan Dushantrao S; Dwivedi F; Kumar G; Kumar Jindal D; Singh C; Dhamija I; Grover P; Kumar S
Eur J Pharm Biopharm; 2024 Jul; 200():114323. PubMed ID: 38754524
[TBL] [Abstract][Full Text] [Related]
78. Current Insights into Combination Therapies with MAPK Inhibitors and Immune Checkpoint Blockade.
Shin MH; Kim J; Lim SA; Kim J; Lee KM
Int J Mol Sci; 2020 Apr; 21(7):. PubMed ID: 32260561
[TBL] [Abstract][Full Text] [Related]
79. Risk Factors and Biomarkers for Immune-Related Adverse Events: A Practical Guide to Identifying High-Risk Patients and Rechallenging Immune Checkpoint Inhibitors.
Chennamadhavuni A; Abushahin L; Jin N; Presley CJ; Manne A
Front Immunol; 2022; 13():779691. PubMed ID: 35558065
[TBL] [Abstract][Full Text] [Related]
80. Implication of the Gut Microbiome and Microbial-Derived Metabolites in Immune-Related Adverse Events: Emergence of Novel Biomarkers for Cancer Immunotherapy.
Dora D; Bokhari SMZ; Aloss K; Takacs P; Desnoix JZ; Szklenárik G; Hurley PD; Lohinai Z
Int J Mol Sci; 2023 Feb; 24(3):. PubMed ID: 36769093
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]